Last updated on October 2018

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Brief description of study

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.

Clinical Study Identifier: NCT02486718

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GO29527 ...

St. Petersburg Med Univ; n.a. I.P. Pavlov; Pulmonology Research
St Petersburg, Russian Federation

Reference Study ID Number: GO29527 ...

City Clinical Oncology Dispensary
Saint-Petersburg, Russian Federation

Reference Study ID Number: GO29527 ...

Leningrad Regional Clinical Hospital
St Petersburg, Russian Federation